Extensive clinicopathologic data allowed us to adjust survival models for multiple variables such as tumor location, tumor grade, disease stage, lymphovascular invasion, MMR status, and BRAF status, strengthening the relevance of the findings. This evidence concerns the gene BRAF and neoplasm.